Amerikanische Gesellschaft für Hirudotherapie

Department of Health and Social Affairs — Federated States of Micronesia

FSM DHSA · Micronesia (Federated States) · oceania

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Federated States of Micronesia DHSA — leech-specific authorisation pathway not independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
oceania
Country
Micronesia (Federated States)
Leech status
unregulated
Last ASH review
2026-05-28

Relevant Regulation Codes

  • FSM Pharmaceutical Practice Act and amendments
  • Compact of Free Association arrangements with the United States as applicable
  • Pacific Island Countries (PIC) joint procurement arrangements through the Pacific Pharmaceutical Procurement Service where applicable

Prescriber Requirements

  • FSM DHSA–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

FSM DHSA registration as applicable; English-language labelling (with state-level vernaculars per local convention). Standard cold-chain conditions, with logistical constraints typical of multi-state Micronesian distribution.

Import/Export Rules

FSM DHSA and Quarantine Division clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

FSM's national health insurance scheme coverage depends on inpatient bundling. Compact-of-Free-Association arrangements with the US may apply.

ASH Editorial Notes

Leech-specific authorisation pathway not independently verified by ASH; falls under general medical-device / traditional-medicine framework as appropriate. FSM Compact of Free Association with the United States introduces complex jurisdictional questions for medical-device classification that ASH has not independently mapped.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.